The company sales and the sales of each drug have attracted much attention, with the 2016 financial reports issued by the international pharmaceutical giants in succession recently. What behind the market data are the general trend changes in the pharmaceutical field, such as the increasingly hot antibody drug market, the increasingly apparent shock to the original drug market by biosimilars, and the increasing acceleration of the new drug R&D mode updating. How to keep up with the pharmaceutical R&D pace and master the pulse of technology is a quite meaningful question. The article intends to understand the meanings behind sales revenue data of each pharmaceutical giant deeply and clearly, by looking at the sales performance of each drug.
I. Humira had a big lead among the global 50 hottest drugs in 2016
I have organized the top 50 drugs by 2016 sales (see the attached table) for the readers to check. The annual sales of the 50 drugs were all above USD 2 billion, including 13 oncology drugs, 7 autoimmune disease drugs, 7 diabetes drugs, 6 nervous system drugs, 6 cardiovascular system drugs, and 5 anti-infective drugs, etc. The total sales of the top 50 were as high as USD 200 billion, and the "miracle drug" Humira continued to be the sales champion with the stunning USD 16 billion performance.
II. Market share of antibody drugs increasingly grew, and so did their sales proportions
The total sales of the top 50 drugs were as high as USD 200 billion according to statistics, wherein, there were 11 antibody drugs. Data show that the global antibody market size was about USD 90 billion in 2016, and the sales of the said 11 antibody drugs were about USD 67.7 billion. Humira, infliximab, rituximab, bevacizumab and trastuzumab have occupied the TOP5 positions for many years with the relevant product revenue accounting for a half.
III. Market impact of biosimilars began to show
Influences of biosimilars on the market share of original drugs could not be ignored, as they continued to be marketed, for example, the sales of infliximab had declined from USD 2.4 billion to 1.2 billion due to the strong impact from the biosimilars; furthermore, the sales of Sanofi’s insulin glargine continued to decline also due to the advantage of the biosimilar Basaglar in the price.
IV. Several "miracle drugs" of giants that can be the mainstay of their companies
AbbVie’s Humira, Gilead’s Harvoni/Solvadi, Celgene’s lenalidomide, and Biogen’s dimethyl fumarate (DMF) are found to be the several drugs that can be the mainstay of their companies, according to my special statistics of the proportions of top50 drugs in the total revenue of respective company, with sales proportion able to reach up to 30%, and some even reaching the stunning 60% sales proportion. In my opinion, the high sales proportion can affect the long-term interests of a company somehow, for example, the HCV "miracle drug" Harvoni/Solvadi of Gilead had lead Gilead’s performance to peak, but the super strong healing power of the drug resulted in the sales to continue to decline and Gilead to fall off the miracle path.
V. Sales performance of Ketruda fell behind Opdivo in the exceptionally hot PD-1 antibody drug market
PD-1 antibody has been a favorite of the antibody drug market in recent years. Chinese enterprises are competing to conduct layout in the PD-1 antibody drug market. The market competition of the 3 marketed drugs has become increasingly fierce. Opdivo won in the continued disputes with Keytruda and enjoyed the billions of revenue from sales of Keytruda. BMS failed the first-line non-small cell lung cancer treatment and gave up the application for accelerated review of Yervoy/Opdivo combination therapy, however, the advantages of Opdivo over Keytruda have appeared, and will continue and become larger.
Attached table:
|
Ranking
|
Drug
|
Indication
|
Company
|
2015
USD 100 million
|
Sales proportion
|
2016
USD 100 million
|
Sales proportion
|
|
1
|
Humira
|
Autoimmune disease
|
AbbVie
|
140.1
|
61.3%
|
160.8
|
63%
|
|
2
|
Harvoni (sofosbuvir+ledipasvir)
|
Anti-infection
|
Gilead
|
138.6
|
42.5%
|
90.8
|
29.9%
|
|
3
|
Enbrel (etanercept)
|
Autoimmune disease
|
Amgen/Pfizer
|
53.6 (Amgen), 33.3 (Pfizer)
|
28% (Amgen), 7% (Pfizer)
|
59.6 (Amgen), 29.1 (Pfizer)
|
26% (Amgen), 6% (Pfizer)
|
|
4
|
Remicade (infliximab)
|
Autoimmune disease
|
J & J/MSD/Mitsubishi Tanabe
|
65.6 (J & J) +17.94 (MSD), 5.7 (Mitsubishi Tanabe)
|
9.4% (J & J) +4.5% (MSD)
|
69.7 (J & J) +12.68 (MSD) +4.6 (Mitsubishi Tanabe)
|
9.6% (J & J) +4.5% (MSD)
|
|
5
|
Rituxan (rituximab)
|
Anti-tumor
|
Roche
|
70.3
|
14.6%
|
72.9
|
14.4%
|
|
6
|
Revlimid (lenalidomide)
|
Anti-tumor
|
Celgene
|
58.01
|
63.3%
|
69.74
|
62.3%
|
|
7
|
Avastin (bevacizumab)
|
Anti-tumor
|
Roche
|
66.8
|
13.9%
|
67.8
|
13.4%
|
|
8
|
Herceptin (trastuzumab)
|
Anti-tumor
|
Roche
|
65.4
|
13.6%
|
67.8
|
13.4%
|
|
9
|
Prevnar (pneumococcal vaccine)
|
Anti-infection
|
Pfizer
|
62.5
|
12.7%
|
57.2
|
10.8%
|
|
10
|
Lantus (insulin glargine)
|
Diabetes
|
Sanofi
|
71.8
|
19.4%
|
64.1
|
19.0%
|
|
11
|
Eylea (aflibercept)
|
Eye disease
|
Regeneron/Bayer
|
40.6
|
-
|
52
|
-
|
|
12
|
Xarelto (rivaroxaban)
|
Cardiovascular drug
|
J & J/Bayer
|
18.8 J & J，23.1 Bayer
|
2.7% J & J
|
22.9 J & J 27 Bayer
|
3.2%
|
|
13
|
Lyrica (pregabalin)
|
Nervous system
|
Pfizer
|
48.4
|
9.9%
|
49.7
|
9.4%
|
|
14
|
c, PEG- filgrastim
|
Anti-tumor
|
Amgen
|
47.2
|
21.8%
|
46.5
|
20.3%
|
|
15
|
Sovaldi (sofosbuvir)
|
Anti-infection
|
Gilead
|
52.8
|
16.2%
|
40.7
|
13.4%
|
|
16
|
Seretide/Advair (fluticasone propionate/salmeterol)
|
Respiratory system
|
GSK
|
41.4
|
11.3%
|
About 39
|
10.3%
|
|
17
|
Copaxone (glatiramer acetate)
|
Nervous system
|
Teva
|
40.2
|
20.4%
|
42.2
|
19.3%
|
|
18
|
Tecfidera (dimethyl fumarate)
|
Nervous system
|
Biogen
|
39.4
|
36.6%
|
39.7
|
34.7%
|
|
19
|
Januvia (sitagliptin)
|
Diabetes
|
MSD
|
38.6
|
9.8%
|
39.1
|
9.8%
|
|
20
|
Opdivo (nivolumab)
|
Anti-tumor
|
BMS
|
9.7
|
5.9%
|
37.7
|
19.4%
|
|
21
|
Truvada (emtricitabine/tenofovir disoproxil fumarate)
|
Anti-infection
|
Gilead
|
34.6
|
10.6%
|
35.7
|
11.7%
|
|
22
|
Crestor (rosuvastatin)
|
Cardiovascular disease
|
AstraZeneca
|
54.2
|
21.9%
|
34
|
14.8%
|
|
23
|
Eliquis (apixaban)
|
Cardiovascular disease
|
BMS
|
18.6
|
11.3%
|
33.4
|
17.2%
|
|
24
|
Gleevec (imatinib)
|
Oncology drug
|
Novartis
|
46.6
|
9.4%
|
33.2
|
6.8%
|
|
25
|
Symbicort (budesonide/formoterol)
|
Respiratory system
|
AstraZeneca
|
33.9
|
13.7%
|
29.9
|
13%
|
|
26
|
Lucentis (ranibizumab)
|
Nervous system
|
Novartis, Chugai Pharmaceutical
|
20.6 Novartis
14.8 Chugai Pharmaceutical
|
4.2% Novartis
NA Chugai Pharmaceutical
|
18.4 Novartis
14 Chugai Pharmaceutical
|
3.8% Novartis
14 Chugai Pharmaceutical
|
|
27
|
Stelara (ustekinumab)
|
Autoimmune disease
|
J & J
|
24.7
|
3.5%
|
32.3
|
4.5%
|
|
28
|
Gilenya (fingolimod)
|
Nervous system
|
Novartis
|
27.8
|
5.6%
|
31.1
|
6.4%
|
|
29
|
Imbruvica (ibrutinib)
|
Anti-tumor
|
J & J/AbbVie
|
6.9 J & J 7.5 AbbVie
|
1% J & J 3.3% AbbVie
|
12.5 J & J 18.3 AbbVie
|
1.7% J & J 7.1%
|
|
30
|
Victoza (liraglutide)
|
Diabetes
|
Novo Nordisk
|
27
|
17.5%
|
29.7
|
18.6%
|
|
31
|
Novolog (insulin aspart)
|
Diabetes
|
Novo Nordisk
|
31.1
|
20.1%
|
29.6
|
18.5%
|
|
32
|
Soliris (eculizumab)
|
Anti-tumor
|
Alexion Pharmaceuticals
|
25.9
|
-
|
28
|
-
|
|
33
|
Humalog
|
Diabetes
|
Eli Lilly
|
28.4
|
14.2%
|
27.7
|
13.1%
|
|
34
|
Zeita (ezetimibe)
|
Diabetes
|
MSD
|
25.3
|
6.4%
|
25.6
|
6.4%
|
|
35
|
Levemir (insulin detemir)
|
Diabetes
|
Novo Nordisk
|
27.5
|
17.8%
|
25.3
|
15.8%
|
|
36
|
Simponi (golimumab)
|
Autoimmune disease
|
J & J/MSD
|
13.3 J & J 6.9 MSD
|
1.9% J & J 1.7% MSD
|
17.5 J & J 7.7 MSD
|
2.4% J & J 1.9% MSD
|
|
37
|
Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
|
Anti-infection
|
Gilead
|
31.3
|
9.6%
|
26.1
|
8.6%
|
|
38
|
Vyvanse (lisdexamfetamine)
|
Nervous system
|
Shire
|
17.2
|
NA
|
23
|
NA
|
|
39
|
Velcade (bortezomib)
|
Nervous system
|
J & J/ Takeda Pharmaceutical
|
13.3 J & J, 14.0 Takeda Pharmaceutical
|
1.9% J & J, NA Takeda Pharmaceutical
|
12.2J & J, 12.7 Takeda Pharmaceutical
|
1.7% J & J, NA Takeda Pharmaceutical
|
|
40
|
Cialis (tadalafil)
|
Cardiovascular disease
|
Eli Lilly
|
23.1
|
11.6%
|
24.7
|
11.6%
|
|
41
|
Xolair (omalizumab)
|
Respiratory system
|
Novartis/Roche
|
7.55 Novartis 12.7 Roche
|
1.5% Novartis 2.6% Roche
|
8.35 Novartis 14.98 Roche
|
1.7% Novartis 3.0% Roche
|
|
42
|
Avonex (interferon)
|
Nervous system
|
Biogen
|
26.3
|
24.4%
|
23.1
|
20.2%
|
|
43
|
Alimta (pemetrexed)
|
Anti-tumor
|
Eli Lilly
|
24.9
|
12.5%
|
22.8
|
10.7%
|
|
44
|
Orencia (abatacept)
|
Autoimmune disease
|
BMS
|
18.9
|
11.5%
|
22.7
|
11.7%
|
|
45
|
Zytiga (abiraterone)
|
Anti-tumor
|
J & J
|
22.3
|
3.2%
|
22.6
|
3.1%
|
|
46
|
Invega (paliperidone)
|
Antipsychotic
|
J & J
|
18.3
|
2.6%
|
22.1
|
3.1%
|
|
47
|
Janumet (sitagliptin/metformin)
|
Diabetes
|
MSD
|
21.5
|
5.4%
|
22
|
5.5%
|
|
48
|
Olmetec (olmesartan)
|
Cardiovascular disease
|
Daiichi Sankyo
|
23.5
|
-
|
22
|
-
|
|
49
|
Gardasil 9 (cervical cancer vaccine)
|
Anti-tumor
|
MSD
|
19.1
|
4.8%
|
21.7
|
5.4%
|
|
50
|
Xtandi (enzalutamide)
|
Anti-tumor
|
Astellas
|
11.31
|
-
|
21.0
|
-
|
- Sales of some drug products consist of two parts separately from different companies in different market regions.
- The sales proportion in the table refers to the proportion of product sales in the company’s annual sales.
- The sales proportions of some companies are not given due to no data found.
|
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
